7. Grifols (NASDAQ:GRFS)
Grifols (NASDAQ: GRFS) holds the seventh spot on our list of the top value stocks to buy under $10, bringing a healthcare and plasma-derived medicines story into the ranking. Trading at $7.42, with the stock down 0.54%, Grifols (NASDAQ: GRFS) may appeal to investors searching for cheap healthcare stocks, biotech value stocks, plasma medicine stocks, rare disease treatment stocks, and undervalued stocks under $10. Unlike many healthcare companies that depend heavily on early-stage trial speculation, Grifols has a long operating history and a global footprint. Founded in Barcelona in 1909, the company provides biopharmaceutical products and medical services in more than 110 countries, giving it a scale and history that many low-priced healthcare stocks simply do not have.
On June 15, Grifols launched FESILTY in the United States for the treatment of acute bleeding in pediatric and adult patients with congenital fibrinogen deficiency, or CFD, excluding dysfibrinogenemia. Congenital fibrinogen deficiency is a rare genetic bleeding disorder where the body lacks enough functional fibrinogen, an important clotting protein needed to stop bleeding and support wound healing. For patients with this condition, bleeding events can become serious and time-sensitive, which makes targeted treatment especially important. That is where FESILTY enters the story. It is a highly purified, human-derived fibrinogen concentrate designed to give physicians a more precise treatment option for acute bleeding situations.
The product is positioned as an improvement over traditional options such as cryoprecipitate or fresh frozen plasma. Those treatments can be useful, but they may require larger-volume infusions, cross-matching, and less predictable dosing. FESILTY offers faster and more predictable dosing, comes in a complete kit, can be stored at room temperature, and can be reconstituted in roughly three minutes. In a clinical setting, especially during time-sensitive bleeding events, speed and dosing precision can matter a great deal. For investors looking at value stocks under $10, the launch provides a concrete business development rather than just a vague growth promise. It gives Grifols another specialized product in the rare disease and plasma-derived medicine space.
The FDA approval for FESILTY was supported by Phase I/III clinical study data confirming its safety, pharmacokinetic properties, and hemostatic efficacy. However, investors should also recognize that the product carries risks, including possible hypersensitivity reactions and thrombotic events, and it is contraindicated in patients with severe hypersensitivity to its components. That said, healthcare stocks often earn investor attention when they combine approved therapies, specialized medical markets, and global commercial infrastructure. Grifols (NASDAQ: GRFS) fits that profile. For investors hunting for cheap stocks to buy under $10, GRFS is not just a low-priced healthcare name. It is a global plasma-focused company with a new US product launch in a rare bleeding disorder market, making it one of the more medically specific value stocks on this list.
Click next to see the following stock...
